Qiubai Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Qiubai Li has a total of 241 co-authors. Here are the top co-authors by number of shared publications:
- Zhichao Chen
Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
20 shared publications Hongxiang Wang
Department of Hematology The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
14 shared publicationsWenlan Chen
Huazhong University of Science and Technology
14 shared publicationsDi Wu
Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
13 shared publicationsLi Chen
Department of Hematology, Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China
11 shared publicationsZhichao Chen
Department of Hematology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
11 shared publications
Latest Publications
- Open Access
- 19 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8326
Characterization of Umbilical Cord Mesenchymal Stromal Cells Overexpressing Klotho and In Vitro Anti-Aging Efficacy of Their Derived Extracellular Vesicles
Age-related degeneration remains a premier biomedical challenge, frequently underpinned by cellular senescence and stem cell dysfunction. Accumulating evidence suggests that umbilical cord mesenchymal stromal cell (UC-MSC)-derived extracellular vesicles (UC-EVs) and the longevity protein Klotho hold great promise as anti-aging biotherapeutics. Here, we strategically engineered UC-MSCs to overexpress Klotho and generated functional Klotho-enriched UC-EVs (KL-EVs). Our data demonstrated that genetic modification endowed UC-MSCs with prominent osteogenic differentiation potency and angiogenesis efficacy. More importantly, KL-EVs profoundly rescued multifaceted senescent phenotypes in both adult bone marrow mesenchymal stem cells (BMSCs) and human renal tubular epithelial cells (HK-2) in vitro. In particular, KL-EVs rescued the age-related differentiation bias of adult BMSCs by robustly prompting their osteogenic differentiation capacity. Taken together, we developed a novel type of UC-MSCs and isolated their EVs enriched with Klotho protein. This strategy integrated and enhanced the anti-aging effects of both entities in vitro, offering a new perspective for counteracting cellular senescence and alleviating age-associated degenerative alterations.
- 19 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8326
Open AccessCharacterization of Umbilical Cord Mesenchymal Stromal Cells Overexpressing Klotho and In Vitro Anti-Aging Efficacy of Their Derived Extracellular Vesicles
Age-related degeneration remains a premier biomedical challenge, frequently underpinned by cellular senescence and stem cell dysfunction. Accumulating evidence suggests that umbilical cord mesenchymal stromal cell (UC-MSC)-derived extracellular vesicles (UC-EVs) and the longevity protein Klotho hold great promise as anti-aging biotherapeutics. Here, we strategically engineered UC-MSCs to overexpress Klotho and generated functional Klotho-enriched UC-EVs (KL-EVs). Our data demonstrated that genetic modification endowed UC-MSCs with prominent osteogenic differentiation potency and angiogenesis efficacy. More importantly, KL-EVs profoundly rescued multifaceted senescent phenotypes in both adult bone marrow mesenchymal stem cells (BMSCs) and human renal tubular epithelial cells (HK-2) in vitro. In particular, KL-EVs rescued the age-related differentiation bias of adult BMSCs by robustly prompting their osteogenic differentiation capacity. Taken together, we developed a novel type of UC-MSCs and isolated their EVs enriched with Klotho protein. This strategy integrated and enhanced the anti-aging effects of both entities in vitro, offering a new perspective for counteracting cellular senescence and alleviating age-associated degenerative alterations.
- Open Access
- 10 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3372-3384
A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial
Early-phase studies of deep B cell depletion with anti-CD19 chimeric antigen receptor (CAR) T have produced prolonged, drug-free remission in refractory autoimmune disease. However, CAR T cell therapy requires lymphodepleting chemotherapy, autologous cell manufacturing and specialized infrastructure, limiting reach to a fraction of patients who might benefit. Bispecific T cell engagers (TCEs) offer a potent, off-the-shelf approach to deep B cell depletion; however, controlled clinical evaluation in rheumatic disease remains limited. Here we report results from the intravenous treatment arm of an ongoing, first-in-disease, phase 1 trial of A-319, a next-generation CD3×CD19 TCE, in 12 patients with active systemic lupus erythematosus (SLE) with 52 weeks of follow-up. Patients received A-319 (0.3−1.2 μg kg−1) three times weekly for 3 weeks after 1 week of priming doses (0.05 μg kg−1). The primary endpoint was safety and tolerability. A-319 demonstrated a favorable safety profile, with no treatment-related serious adverse events, deaths, grade 3 or higher cytokine release syndrome (CRS) or neurotoxicity; CRS was predominantly grade 1 (91.6%, 11/12), and hematologic toxicity was minimal. Secondary endpoints (pharmacokinetics, pharmacodynamics and immunogenicity) demonstrated linear pharmacokinetics and dose-dependent B cell depletion, with complete peripheral depletion in higher-dose cohorts. Among exploratory efficacy endpoints, 80% (8/10) of patients achieved Lupus Low Disease Activity State (LLDAS), and 60% (6/10) achieved Definition of Remission in SLE (DORIS) at 12 months, accompanied by sustained reductions in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores, autoantibody titers and proteinuria. Exploratory serial single-cell RNA sequencing revealed broad immune reprogramming mechanistically similar to that after CD19 CAR T cell therapy in SLE, including multi-lineage suppression of SLE-associated interferon response signatures across B cell, T cell and myeloid compartments and near-complete reconstitution of the B cell repertoire. Together, these findings demonstrate the feasibility, safety and preliminary efficacy of CD3×CD19 T cell engagement in SLE and support further clinical development of TCEs in controlled, pivotal studies. ClinicalTrials.gov identifier: NCT06400537.
- 10 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3372-3384
Open AccessA bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial
Early-phase studies of deep B cell depletion with anti-CD19 chimeric antigen receptor (CAR) T have produced prolonged, drug-free remission in refractory autoimmune disease. However, CAR T cell therapy requires lymphodepleting chemotherapy, autologous cell manufacturing and specialized infrastructure, limiting reach to a fraction of patients who might benefit. Bispecific T cell engagers (TCEs) offer a potent, off-the-shelf approach to deep B cell depletion; however, controlled clinical evaluation in rheumatic disease remains limited. Here we report results from the intravenous treatment arm of an ongoing, first-in-disease, phase 1 trial of A-319, a next-generation CD3×CD19 TCE, in 12 patients with active systemic lupus erythematosus (SLE) with 52 weeks of follow-up. Patients received A-319 (0.3−1.2 μg kg−1) three times weekly for 3 weeks after 1 week of priming doses (0.05 μg kg−1). The primary endpoint was safety and tolerability. A-319 demonstrated a favorable safety profile, with no treatment-related serious adverse events, deaths, grade 3 or higher cytokine release syndrome (CRS) or neurotoxicity; CRS was predominantly grade 1 (91.6%, 11/12), and hematologic toxicity was minimal. Secondary endpoints (pharmacokinetics, pharmacodynamics and immunogenicity) demonstrated linear pharmacokinetics and dose-dependent B cell depletion, with complete peripheral depletion in higher-dose cohorts. Among exploratory efficacy endpoints, 80% (8/10) of patients achieved Lupus Low Disease Activity State (LLDAS), and 60% (6/10) achieved Definition of Remission in SLE (DORIS) at 12 months, accompanied by sustained reductions in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores, autoantibody titers and proteinuria. Exploratory serial single-cell RNA sequencing revealed broad immune reprogramming mechanistically similar to that after CD19 CAR T cell therapy in SLE, including multi-lineage suppression of SLE-associated interferon response signatures across B cell, T cell and myeloid compartments and near-complete reconstitution of the B cell repertoire. Together, these findings demonstrate the feasibility, safety and preliminary efficacy of CD3×CD19 T cell engagement in SLE and support further clinical development of TCEs in controlled, pivotal studies. ClinicalTrials.gov identifier: NCT06400537.
- Open Access
- 14 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7263
Size-Based Proteomic Signatures of Extracellular Vesicles Derived from Umbilical Cord Mesenchymal Stem Cells Fractionated by EXODUS
Umbilical cord mesenchymal stem cell-derived extracellular vesicles (UCMSC-EVs) hold strong promise for regenerative medicine, yet their intrinsic size heterogeneity remains a critical barrier to clinical translation, as it obscures molecular and functional specialization within bulk EV preparations. Here, we pioneer the application of the automated EXODUS platform to directly fractionate EVs from cell culture supernatants, resolving bulk UCMSC-EVs into three size-defined subpopulations. By integrating this platform with high-resolution mass spectrometry, we systematically characterize the molecular and functional landscapes of these UCMSC-EV size subpopulations. We demonstrate that EV size is tightly linked to distinct biogenetic origins, biomolecular corona composition, and functional programs: smaller EVs are enriched in exosome-associated proteins, ECM–glycan interfaces, and corona-associated molecules, and preferentially engage endocytosis- and phagosome-related pathways, whereas larger EVs exhibit ectosomal signatures. These findings identify EV size as a critical determinant of molecular architecture and biological function, providing insight into size-dependent EV heterogeneity and informing the rational design and optimization of UCMSC-EV-based therapeutic strategies.
- 14 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7263
Open AccessSize-Based Proteomic Signatures of Extracellular Vesicles Derived from Umbilical Cord Mesenchymal Stem Cells Fractionated by EXODUS
Umbilical cord mesenchymal stem cell-derived extracellular vesicles (UCMSC-EVs) hold strong promise for regenerative medicine, yet their intrinsic size heterogeneity remains a critical barrier to clinical translation, as it obscures molecular and functional specialization within bulk EV preparations. Here, we pioneer the application of the automated EXODUS platform to directly fractionate EVs from cell culture supernatants, resolving bulk UCMSC-EVs into three size-defined subpopulations. By integrating this platform with high-resolution mass spectrometry, we systematically characterize the molecular and functional landscapes of these UCMSC-EV size subpopulations. We demonstrate that EV size is tightly linked to distinct biogenetic origins, biomolecular corona composition, and functional programs: smaller EVs are enriched in exosome-associated proteins, ECM–glycan interfaces, and corona-associated molecules, and preferentially engage endocytosis- and phagosome-related pathways, whereas larger EVs exhibit ectosomal signatures. These findings identify EV size as a critical determinant of molecular architecture and biological function, providing insight into size-dependent EV heterogeneity and informing the rational design and optimization of UCMSC-EV-based therapeutic strategies.
- 25 June 2026
- Published by Taylor & Francis in Nanomedicine
- Vol. 21 (13) , 1-11
UCMSC-Exo for chemotherapy-induced myelosuppression in acute myeloid leukemia: a phase I clinical trial protocol
Myelosuppression induced by chemotherapy represents a critical bottleneck for patients with hematological malignancies, leading to a series of severe complications responsible for chemotherapy dose reduction, interruptions, and even treatment-related death. There exists an urgent need for strategies to repair the bone marrow microenvironment and thus promote early recovery from myelosuppression. Umbilical cord-derived mesenchymal stem cell exosomes (UCMSC-Exo), as the key effector of stem cells, exhibit multi-target characteristics, making them a promising candidate for bone marrow structural reconstruction and functional remodeling. This study is a single-arm, open-label, dose-escalation, single-center, phase I clinical trial designed to evaluate the safety, tolerability, and preliminary efficacy of UCMSC-Exo in the treatment of chemotherapy-induced myelosuppression in patients with acute myeloid leukemia. Nine to eighteen eligible participants will be enrolled sequentially into three UCMSC-Exo dose-escalation groups to receive a single infusion, after which they will be followed up for 12 months. The primary endpoints focus on safety and tolerability. Secondary endpoints include parameters assessing myelosuppression recovery, the incidence of myelosuppression-related complications, and supportive care. The study protocol has been approved by the Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.Clinical trial registration: NCT06245746.
- 25 June 2026
- Published by Taylor & Francis in Nanomedicine
- Vol. 21 (13) , 1-11
UCMSC-Exo for chemotherapy-induced myelosuppression in acute myeloid leukemia: a phase I clinical trial protocol
Myelosuppression induced by chemotherapy represents a critical bottleneck for patients with hematological malignancies, leading to a series of severe complications responsible for chemotherapy dose reduction, interruptions, and even treatment-related death. There exists an urgent need for strategies to repair the bone marrow microenvironment and thus promote early recovery from myelosuppression. Umbilical cord-derived mesenchymal stem cell exosomes (UCMSC-Exo), as the key effector of stem cells, exhibit multi-target characteristics, making them a promising candidate for bone marrow structural reconstruction and functional remodeling. This study is a single-arm, open-label, dose-escalation, single-center, phase I clinical trial designed to evaluate the safety, tolerability, and preliminary efficacy of UCMSC-Exo in the treatment of chemotherapy-induced myelosuppression in patients with acute myeloid leukemia. Nine to eighteen eligible participants will be enrolled sequentially into three UCMSC-Exo dose-escalation groups to receive a single infusion, after which they will be followed up for 12 months. The primary endpoints focus on safety and tolerability. Secondary endpoints include parameters assessing myelosuppression recovery, the incidence of myelosuppression-related complications, and supportive care. The study protocol has been approved by the Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.Clinical trial registration: NCT06245746.
- Open Access
- 10 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1723572
MSC-derived microvesicles inhibit the progression of arthritis in a murine model of preclinical rheumatoid arthritis
Objective: Preclinical rheumatoid arthritis (Pre-RA) represents a critical stage before the clinical manifestation of RA, characterized by autoimmune dysregulation. Early intervention in this stage can prevent the progression to full-blown RA. This study aimed to develop a robust murine model of Pre-RA and measure the therapeutic potential of mesenchymal stem cell-derived microvesicles (MSC-MVs) as a novel strategy to prevent the onset and progression of autoimmune arthritis. Methods: Low-concentration collagen emulsion was administered subcutaneously at the tail base on days 0 and 21 to establish the preclinical collagen-induced arthritis (Pre-CIA) model. Disease progression was assessed over 45 days based on CIA scoring, body weight monitoring, CT images, histopathology, laboratory tests, and flow cytometry. Pre-CIA mice were treated with MSC-MVs. The pharmacokinetic characteristics of MSC-MVs were measured using in vivo fluorescence imaging, and therapeutic efficacy was evaluated through CIA scoring, joint inflammation analysis, complementary imaging, and immunological assays. Results: We established a mouse model of Pre-CIA characterized by mild arthritis using reduced doses of immunizing agents. Pre-CIA mice were less likely to experience arthritis (59.09%) than CIA mice (95.45%). In addition, Pre-CIA mice exhibited gradual increases in CIA scores and increased histological damage, consistent with Pre-RA. LPS injection accelerated the rapid progression from Pre-CIA to CIA. Micro-CT revealed mild trabecular bone loss and joint erosion in Pre-CIA mice compared to severe damage in CIA mice. Histological staining demonstrated intermediate cartilage and bone damage in Pre-CIA mice, with significant synovial hyperplasia and cartilage loss. The serum levels of pro-inflammatory markers (IL-1β, TNF-α, IL-6, and CRP P<0.05) and RA-specific autoantibodies (anti-CII, and anti-CCP P<0.05) were upregulated in Pre-CIA mice. Flow cytometry revealed immune imbalances in Pre-CIA mice, with a decreased abundance of Tregs and Th2 cells and an increased abundance of Th1, Th17, and Tfh cells. Treatment with MVs prevented the progression of arthritis in Pre-CIA mice, reduced inflammatory marker levels, stabilized bone and cartilage integrity, and restored immune balance. Conclusions: The Pre-CIA model effectively reflects the key pathological and immunological features of Pre-RA, providing a robust platform for studying disease mechanisms and early therapeutic interventions. Treatment with MSC-MVs successfully showed reversal of pathological features, highlighting their potential as a novel therapeutic strategy for preventing the progression of Pre-RA to full-blown rheumatoid arthritis. These findings underscore the clinical significance of MSC-MVs in addressing unmet needs in the early management of RA.
- 10 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1723572
Open AccessMSC-derived microvesicles inhibit the progression of arthritis in a murine model of preclinical rheumatoid arthritis
Objective: Preclinical rheumatoid arthritis (Pre-RA) represents a critical stage before the clinical manifestation of RA, characterized by autoimmune dysregulation. Early intervention in this stage can prevent the progression to full-blown RA. This study aimed to develop a robust murine model of Pre-RA and measure the therapeutic potential of mesenchymal stem cell-derived microvesicles (MSC-MVs) as a novel strategy to prevent the onset and progression of autoimmune arthritis. Methods: Low-concentration collagen emulsion was administered subcutaneously at the tail base on days 0 and 21 to establish the preclinical collagen-induced arthritis (Pre-CIA) model. Disease progression was assessed over 45 days based on CIA scoring, body weight monitoring, CT images, histopathology, laboratory tests, and flow cytometry. Pre-CIA mice were treated with MSC-MVs. The pharmacokinetic characteristics of MSC-MVs were measured using in vivo fluorescence imaging, and therapeutic efficacy was evaluated through CIA scoring, joint inflammation analysis, complementary imaging, and immunological assays. Results: We established a mouse model of Pre-CIA characterized by mild arthritis using reduced doses of immunizing agents. Pre-CIA mice were less likely to experience arthritis (59.09%) than CIA mice (95.45%). In addition, Pre-CIA mice exhibited gradual increases in CIA scores and increased histological damage, consistent with Pre-RA. LPS injection accelerated the rapid progression from Pre-CIA to CIA. Micro-CT revealed mild trabecular bone loss and joint erosion in Pre-CIA mice compared to severe damage in CIA mice. Histological staining demonstrated intermediate cartilage and bone damage in Pre-CIA mice, with significant synovial hyperplasia and cartilage loss. The serum levels of pro-inflammatory markers (IL-1β, TNF-α, IL-6, and CRP P<0.05) and RA-specific autoantibodies (anti-CII, and anti-CCP P<0.05) were upregulated in Pre-CIA mice. Flow cytometry revealed immune imbalances in Pre-CIA mice, with a decreased abundance of Tregs and Th2 cells and an increased abundance of Th1, Th17, and Tfh cells. Treatment with MVs prevented the progression of arthritis in Pre-CIA mice, reduced inflammatory marker levels, stabilized bone and cartilage integrity, and restored immune balance. Conclusions: The Pre-CIA model effectively reflects the key pathological and immunological features of Pre-RA, providing a robust platform for studying disease mechanisms and early therapeutic interventions. Treatment with MSC-MVs successfully showed reversal of pathological features, highlighting their potential as a novel therapeutic strategy for preventing the progression of Pre-RA to full-blown rheumatoid arthritis. These findings underscore the clinical significance of MSC-MVs in addressing unmet needs in the early management of RA.
- Open Access
- 13 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 9080
Munc13-4 mediates tumor immune evasion by regulating the sorting and secretion of PD-L1 via exosomes
Tumor-derived exosomes carry programmed death-ligand 1 (PD-L1), which binds programmed cell death protein 1 (PD-1) on T cells, suppressing immune responses locally and systemically. However, the mechanisms governing exosomal PD-L1 sorting and secretion remain elusive. Here, we identify Munc13-4 as a crucial regulator of this process. Deletion of Munc13-4 in breast tumors enhances T cell-mediated anti-tumor immunity, suppresses tumor growth, and improves the efficacy of immune checkpoint inhibitors. Mechanistically, Munc13-4 collaborates with hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), Rab27, and SNAREs to facilitate PD-L1 sorting and secretion via exosomes. Cryogenic electron microscopy (cryo-EM) analysis of the Munc13-4–Rab27a complex provide structural insights into exosome secretion. Importantly, PD-L1 sorting relies on a ternary complex composed of Munc13-4, PD-L1 and HRS, which is regulated by interferon gamma (IFNγ) signaling. A designed peptide that disrupts Munc13-4–PD-L1 interaction impedes PD-L1 sorting, enhances antitumor immunity, and suppresses tumor growth, highlighting the therapeutic potential of targeting this pathway.
- 13 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 9080
Open AccessMunc13-4 mediates tumor immune evasion by regulating the sorting and secretion of PD-L1 via exosomes
Tumor-derived exosomes carry programmed death-ligand 1 (PD-L1), which binds programmed cell death protein 1 (PD-1) on T cells, suppressing immune responses locally and systemically. However, the mechanisms governing exosomal PD-L1 sorting and secretion remain elusive. Here, we identify Munc13-4 as a crucial regulator of this process. Deletion of Munc13-4 in breast tumors enhances T cell-mediated anti-tumor immunity, suppresses tumor growth, and improves the efficacy of immune checkpoint inhibitors. Mechanistically, Munc13-4 collaborates with hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), Rab27, and SNAREs to facilitate PD-L1 sorting and secretion via exosomes. Cryogenic electron microscopy (cryo-EM) analysis of the Munc13-4–Rab27a complex provide structural insights into exosome secretion. Importantly, PD-L1 sorting relies on a ternary complex composed of Munc13-4, PD-L1 and HRS, which is regulated by interferon gamma (IFNγ) signaling. A designed peptide that disrupts Munc13-4–PD-L1 interaction impedes PD-L1 sorting, enhances antitumor immunity, and suppresses tumor growth, highlighting the therapeutic potential of targeting this pathway.
- Open Access
- 18 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Stabilizing a mammalian RNA thermometer confers neuroprotection in subarachnoid hemorrhage
Mammals tightly regulate their core body temperature, yet how cells sense and respond to small temperature changes remains incompletely understood. Here, we discover RNA G-quadruplexes (rG4s) as key thermosensors enriched near splice sites of cold-repressed exons. These thermosensing RNA structures, when stabilized, mask splice sites, reducing exon inclusion. Specifically, rG4s near splice sites of a cold-repressed poison exon in the neuroprotective RBM3 are stabilized at low temperatures, leading to exon exclusion. This enables evasion of nonsense-mediated decay, increasing RBM3 expression at cold. Importantly, stabilizing rG4 through increasing intracellular potassium with an FDA-approved potassium channel blocker, mimics the hypothermic effect on alternative splicing, thereby increasing RBM3 expression, leading to RBM3-dependent neuroprotection in a mouse model of subarachnoid hemorrhage. Our findings unveil a mechanism how mammalian RNAs directly sense temperature and potassium perturbations, integrating them into gene expression programs. This opens new avenues for treating diseases arising from splicing defects and disorders benefiting from therapeutic hypothermia, especially hemorrhagic stroke.
- 18 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Open AccessStabilizing a mammalian RNA thermometer confers neuroprotection in subarachnoid hemorrhage
Mammals tightly regulate their core body temperature, yet how cells sense and respond to small temperature changes remains incompletely understood. Here, we discover RNA G-quadruplexes (rG4s) as key thermosensors enriched near splice sites of cold-repressed exons. These thermosensing RNA structures, when stabilized, mask splice sites, reducing exon inclusion. Specifically, rG4s near splice sites of a cold-repressed poison exon in the neuroprotective RBM3 are stabilized at low temperatures, leading to exon exclusion. This enables evasion of nonsense-mediated decay, increasing RBM3 expression at cold. Importantly, stabilizing rG4 through increasing intracellular potassium with an FDA-approved potassium channel blocker, mimics the hypothermic effect on alternative splicing, thereby increasing RBM3 expression, leading to RBM3-dependent neuroprotection in a mouse model of subarachnoid hemorrhage. Our findings unveil a mechanism how mammalian RNAs directly sense temperature and potassium perturbations, integrating them into gene expression programs. This opens new avenues for treating diseases arising from splicing defects and disorders benefiting from therapeutic hypothermia, especially hemorrhagic stroke.
- Open Access
- 6 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (16) , e041440
Ring Finger Protein 2 Promotes Oxidative Stress and Mitochondrial Dysfunction in Doxorubicin‐Induced Cardiotoxicity Via the Mercaptopyruvate Sulfurtransferase/Hydrogen Sulfide Pathway
Background: Doxorubicindoxorubicin, a broad‐spectrum chemotherapy drug, is often associated with dosage‐dependent cardiotoxicity, which results in its limited clinical application. A therapeutic dose of doxorubicin can activate cardiac ubiquitin‐proteasome system, whereas the role and potential mechanisms of this process in doxorubicin‐induced cardiomyopathy (DIC) remain unclear. Herein, we assessed the potential role and therapeutic value of RNF2 (ring finger protein 2) on doxorubicin‐induced cardiac damage. Methods: Cardiomyocyte‐specific RNF2 knockout or overexpression mice received doxorubicin intraperitoneal injection to establish the DIC model. The effects of RNF2 and its downstream mediators were explored through RNA sequencing, immunoprecipitation mass spectrometry analysis, and protein pulldown analysis. Results: The expression of RNF2 was significantly increased in doxorubicin‐treated murine myocardium and neonatal rat ventricular myocytes. Cardiomyocyte‐specific RNF2 overexpression resulted in exaggerated DIC accompanied by increased cardiac dysfunction, fibrosis and apoptosis. Cardiac damage was mitigated in α‐myosin heavy chain promoter‐driven heterozygous‐Cre + /RNF2‐floxed mice. Previous studies have demonstrated that mitochondrial dysfunction and oxidative stress are crucial in DIC and are promoted by RNF2 overexpression and impeded by RNF2 knockout. Mechanistically, RNF2 directly interacted with mercaptopyruvate sulfurtransferase, followed by the ubiquitination and accelerated degradation of mercaptopyruvate sulfurtransferase to decrease hydrogen sulfide accumulation, thereby contributing to more severe oxidative damage and mitochondrial morphofunctional defects. Moreover, mercaptopyruvate sulfurtransferase overexpression or hydrogen sulfide supplementation in cardiomyocyte‐specific RNF2‐overexpressing mice restored cardiac performance after doxorubicin challenge. Conclusions: Our findings reveal the role of RNF2 in oxidative stress and mitochondrial homeostasis and the progression of DIC, suggesting that targeting RNF2 may be a potential therapeutic benefit for DIC.
- 6 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (16) , e041440
Open AccessRing Finger Protein 2 Promotes Oxidative Stress and Mitochondrial Dysfunction in Doxorubicin‐Induced Cardiotoxicity Via the Mercaptopyruvate Sulfurtransferase/Hydrogen Sulfide Pathway
Background: Doxorubicindoxorubicin, a broad‐spectrum chemotherapy drug, is often associated with dosage‐dependent cardiotoxicity, which results in its limited clinical application. A therapeutic dose of doxorubicin can activate cardiac ubiquitin‐proteasome system, whereas the role and potential mechanisms of this process in doxorubicin‐induced cardiomyopathy (DIC) remain unclear. Herein, we assessed the potential role and therapeutic value of RNF2 (ring finger protein 2) on doxorubicin‐induced cardiac damage. Methods: Cardiomyocyte‐specific RNF2 knockout or overexpression mice received doxorubicin intraperitoneal injection to establish the DIC model. The effects of RNF2 and its downstream mediators were explored through RNA sequencing, immunoprecipitation mass spectrometry analysis, and protein pulldown analysis. Results: The expression of RNF2 was significantly increased in doxorubicin‐treated murine myocardium and neonatal rat ventricular myocytes. Cardiomyocyte‐specific RNF2 overexpression resulted in exaggerated DIC accompanied by increased cardiac dysfunction, fibrosis and apoptosis. Cardiac damage was mitigated in α‐myosin heavy chain promoter‐driven heterozygous‐Cre + /RNF2‐floxed mice. Previous studies have demonstrated that mitochondrial dysfunction and oxidative stress are crucial in DIC and are promoted by RNF2 overexpression and impeded by RNF2 knockout. Mechanistically, RNF2 directly interacted with mercaptopyruvate sulfurtransferase, followed by the ubiquitination and accelerated degradation of mercaptopyruvate sulfurtransferase to decrease hydrogen sulfide accumulation, thereby contributing to more severe oxidative damage and mitochondrial morphofunctional defects. Moreover, mercaptopyruvate sulfurtransferase overexpression or hydrogen sulfide supplementation in cardiomyocyte‐specific RNF2‐overexpressing mice restored cardiac performance after doxorubicin challenge. Conclusions: Our findings reveal the role of RNF2 in oxidative stress and mitochondrial homeostasis and the progression of DIC, suggesting that targeting RNF2 may be a potential therapeutic benefit for DIC.
- Open Access
- 2 May 2025
- Published by Wiley in Clinical and Translational Medicine
- Vol. 15 (5) , e70327
Targeting capacity, safety and efficacy of engineered extracellular vesicles delivered by transdermal microneedles to treat plasmacytoma in mice
Background: Engineered extracellular vesicles (EVs) are emerging as a highly potential platform for targeted drug delivery in cancer therapy. Although intravenous injection is commonly used in EV treatment, there is growing interest in using microneedles (MNs) for transdermal EV delivery; however, comprehensive studies comparing the tissue distribution, safety and antitumour efficacy of these two approaches for delivering engineered EVs remain scarce.Methods: We used EVs derived from umbilical cord mesenchymal stem cells, modified with phospholipid‒polyethylene glycol‒N‐hydroxysuccinimide and conjugated with CD38 peptides (CD38‐EVs), to target myeloma cells that highly express CD38 antigen, and tested their safety and antitumour efficacy in mice with subcutaneous plasmacytoma, administrated via dissolvable transdermal MNs or intravenous injection. Flow cytometry, immunofluorescence and fluorescence molecular projection imaging analysis were employed to evaluate the distribution of CD38‐EVs at the cellular level and within living systems. Additionally, histopathological analysis and biochemical analyses were conducted to assess the antitumour effects and safety of CD38‐EVs loaded with doxorubicin (CD38‐EVs‐Dox).Results: Compared to standard EVs, CD38‐EVs exhibited enhanced uptake by CD38high tumour cells and reduced uptake by CD38‐negative non‐tumour cells in vitro. In plasmacytoma NOD/SCID mouse models, CD38‐EVs encapsulated within MNs (CD38‐EVsMNs) effectively targeted the tumour cells much more than the standard EVs encapsulated within MNs (EVsMNs) and CD38‐EVs intravenously administrated (CD38‐EVsi.v), with reduced distribution to the lungs and spleen. Additionally, CD38‐EVs‐Dox induced significantly greater cytotoxicity against the tumour cells than EVs‐Dox in vitro, and CD38‐EVs‐DoxMNs significantly reduced tumour burden compared to both EVs‐DoxMNs and CD38‐EVs‐Doxi.v, while maintaining favourable safety profiles.Conclusions: CD38‐EVs‐DoxMNs have superior efficacy and safety in treating plasmacytoma mice, compared to CD38‐EVs‐Doxi.v, providing novel insights into the potential of MNs as a platform for delivering targeted engineered EVs in tumour therapy.Highlights: Enhanced tumor targeting: CD38‐modified EVs (CD38‐EVs) showed increased uptake by CD38high tumor cells while reducing uptake by CD38‐negative non‐tumor cells. Optimized delivery: MN‐loaded CD38‐EVs targeted tumors more effectively than MN‐loaded EVs and intravenously injected CD38‐EVs, with lower lung and spleen accumulation. Superior antitumor efficacy: MN‐delivered CD38‐EVs‐Dox significantly suppressed tumor growth, outperforming intravenous CD38‐EVs‐Dox and MN‐delivered EVs‐Dox.
- 2 May 2025
- Published by Wiley in Clinical and Translational Medicine
- Vol. 15 (5) , e70327
Open AccessTargeting capacity, safety and efficacy of engineered extracellular vesicles delivered by transdermal microneedles to treat plasmacytoma in mice
Background: Engineered extracellular vesicles (EVs) are emerging as a highly potential platform for targeted drug delivery in cancer therapy. Although intravenous injection is commonly used in EV treatment, there is growing interest in using microneedles (MNs) for transdermal EV delivery; however, comprehensive studies comparing the tissue distribution, safety and antitumour efficacy of these two approaches for delivering engineered EVs remain scarce.Methods: We used EVs derived from umbilical cord mesenchymal stem cells, modified with phospholipid‒polyethylene glycol‒N‐hydroxysuccinimide and conjugated with CD38 peptides (CD38‐EVs), to target myeloma cells that highly express CD38 antigen, and tested their safety and antitumour efficacy in mice with subcutaneous plasmacytoma, administrated via dissolvable transdermal MNs or intravenous injection. Flow cytometry, immunofluorescence and fluorescence molecular projection imaging analysis were employed to evaluate the distribution of CD38‐EVs at the cellular level and within living systems. Additionally, histopathological analysis and biochemical analyses were conducted to assess the antitumour effects and safety of CD38‐EVs loaded with doxorubicin (CD38‐EVs‐Dox).Results: Compared to standard EVs, CD38‐EVs exhibited enhanced uptake by CD38high tumour cells and reduced uptake by CD38‐negative non‐tumour cells in vitro. In plasmacytoma NOD/SCID mouse models, CD38‐EVs encapsulated within MNs (CD38‐EVsMNs) effectively targeted the tumour cells much more than the standard EVs encapsulated within MNs (EVsMNs) and CD38‐EVs intravenously administrated (CD38‐EVsi.v), with reduced distribution to the lungs and spleen. Additionally, CD38‐EVs‐Dox induced significantly greater cytotoxicity against the tumour cells than EVs‐Dox in vitro, and CD38‐EVs‐DoxMNs significantly reduced tumour burden compared to both EVs‐DoxMNs and CD38‐EVs‐Doxi.v, while maintaining favourable safety profiles.Conclusions: CD38‐EVs‐DoxMNs have superior efficacy and safety in treating plasmacytoma mice, compared to CD38‐EVs‐Doxi.v, providing novel insights into the potential of MNs as a platform for delivering targeted engineered EVs in tumour therapy.Highlights: Enhanced tumor targeting: CD38‐modified EVs (CD38‐EVs) showed increased uptake by CD38high tumor cells while reducing uptake by CD38‐negative non‐tumor cells. Optimized delivery: MN‐loaded CD38‐EVs targeted tumors more effectively than MN‐loaded EVs and intravenously injected CD38‐EVs, with lower lung and spleen accumulation. Superior antitumor efficacy: MN‐delivered CD38‐EVs‐Dox significantly suppressed tumor growth, outperforming intravenous CD38‐EVs‐Dox and MN‐delivered EVs‐Dox.
- Top Cited PapersOpen Access
- 1 March 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 3175-3199
Extracellular Vesicles: A Review of Their Therapeutic Potentials, Sources, Biodistribution, and Administration Routes
Extracellular vesicles (EVs) participate in intercellular communication and play an essential role in physiological and pathological processes. In recent years, EVs have garnered significant attention as cell-free therapeutic alternatives, vectors for drug and gene delivery, biomarkers for disease diagnosis and prognosis, vaccine development, and nutraceuticals. The biodistribution of EVs critically influences their efficacy and toxicity. Therefore, this review aims to discuss the main factors influencing the biodistribution of unmodified EVs, highlighting their distribution patterns, advantages, limitations, and applications under different routes of administration. In addition, we provide a comprehensive discussion of the currently available sources of EVs and summarize the current status of the therapeutic potentials of EVs. By optimizing administration routes and selecting appropriate EV sources, we aim to offer valuable insights to enhance the delivery efficiency and therapeutic efficacy of EVs to target tissues.
- 1 March 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 3175-3199
Top Cited PapersOpen AccessExtracellular Vesicles: A Review of Their Therapeutic Potentials, Sources, Biodistribution, and Administration Routes
Extracellular vesicles (EVs) participate in intercellular communication and play an essential role in physiological and pathological processes. In recent years, EVs have garnered significant attention as cell-free therapeutic alternatives, vectors for drug and gene delivery, biomarkers for disease diagnosis and prognosis, vaccine development, and nutraceuticals. The biodistribution of EVs critically influences their efficacy and toxicity. Therefore, this review aims to discuss the main factors influencing the biodistribution of unmodified EVs, highlighting their distribution patterns, advantages, limitations, and applications under different routes of administration. In addition, we provide a comprehensive discussion of the currently available sources of EVs and summarize the current status of the therapeutic potentials of EVs. By optimizing administration routes and selecting appropriate EV sources, we aim to offer valuable insights to enhance the delivery efficiency and therapeutic efficacy of EVs to target tissues.